Loading...
A recent 16-week study showed that dupilumab (Dupixent; a monoclonal antibody that blocks the activity of several cytokines) was safe and effective for managing atopic dermatitis (AD; NEJM JW Gen Med Nov 15 2016 and N Engl J Med 2016; 375:2335). Researchers now have performed a longer industry-funded trial in which they allowed patients to continue standard-of-care topical medications.
More than 600 adults with moderate-to-severe AD were randomized to subcutaneous dupilumab injections or placebo every 1 or 2 weeks for 1 year. Standard AD care was continued, including use of topical steroids and, if needed, topical calcineurin inhibitors. At 16 weeks, 39% of dupilumab patients experienced near-total or total relief compared with 12% of placeb…